| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial DM Harper, EL Franco, C Wheeler, DG Ferris, D Jenkins, A Schuind, ... The lancet 364 (9447), 1757-1765, 2004 | 2382 | 2004 |
| Sustained efficacy up to 4· 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial DM Harper, EL Franco, CM Wheeler, AB Moscicki, B Romanowski, ... The Lancet 367 (9518), 1247-1255, 2006 | 2261 | 2006 |
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a … J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ... The Lancet 374 (9686), 301-314, 2009 | 2071 | 2009 |
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of … J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ... The Lancet 369 (9580), 2161-2170, 2007 | 1678 | 2007 |
| Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double … M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ... The lancet oncology 13 (1), 89-99, 2012 | 895 | 2012 |
| Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis … CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ... The lancet oncology 13 (1), 100-110, 2012 | 614 | 2012 |
| Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. WCM Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR ... Lancet oncology 16, 775-86, 2015 | 346 | 2015 |
| Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination PS Naud, CM Roteli-Martins, NS De Carvalho, JC Teixeira, PC de Borba, ... Human vaccines & immunotherapeutics 10 (8), 2147-2162, 2014 | 323 | 2014 |
| Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up CM Roteli-Martins, P Naud, P De Borba, JC Teixeira, NS De Carvalho, ... Human vaccines & immunotherapeutics 8 (3), 390-397, 2012 | 245 | 2012 |
| Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women N De Carvalho, J Teixeira, CM Roteli-Martins, P Naud, P De Borba, ... Vaccine 28 (38), 6247-6255, 2010 | 229 | 2010 |
| Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study U Jaisamrarn, X Castellsague, SM Garland, P Naud, J Palmroth, ... PloS one 8 (11), e79260, 2013 | 189 | 2013 |
| Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18 A Szarewski, WAJ Poppe, SR Skinner, CM Wheeler, J Paavonen, P Naud, ... International journal of cancer 131 (1), 106-116, 2012 | 172 | 2012 |
| Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial ER Bahmanyar, J Paavonen, P Naud, J Salmerón, SN Chow, D Apter, ... Gynecologic oncology 127 (3), 440-450, 2012 | 140 | 2012 |
| Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc … SM Garland, J Paavonen, U Jaisamrarn, P Naud, J Salmerón, SN Chow, ... International journal of cancer 139 (12), 2812-2826, 2016 | 132 | 2016 |
| Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6· 4 years GlaxoSmithKline Vaccine HPV-007 Study Group The Lancet 374 (9706), 1975-1985, 2009 | 117 | 2009 |
| Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation A Szarewski, SR Skinner, SM Garland, B Romanowski, TF Schwarz, ... The Journal of infectious diseases 208 (9), 1391-1396, 2013 | 93 | 2013 |
| HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRI-CIA … J Paavonen Lancet 374, 301-314, 2009 | 84 | 2009 |
| Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women H Trottier, SM Mahmud, L Lindsay, D Jenkins, W Quint, SL Wieting, ... Cancer Epidemiology Biomarkers & Prevention 18 (3), 854-862, 2009 | 77 | 2009 |
| Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control … X Castellsagué, P Naud, SN Chow, CM Wheeler, MJV Germar, ... The Journal of infectious diseases 210 (4), 517-534, 2014 | 71 | 2014 |
| Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine S Gall, J Teixeira, C Wheeler, P Naud, D Harper, E Franco, W Quint, ... Cancer Research 67 (9_Supplement), 4900-4900, 2007 | 69 | 2007 |
